INTRODUCTION
============

Acute kidney injury (AKI) is a common complication of cardiac surgery, particularly when using the cardiopulmonary bypass (CPB) system. AKI after open heart surgery is known to be associated with increased postoperative mortality, morbidity, and in-hospital costs; reduced postoperative survival rate; and adverse patient outcomes \[[@b1-kjtcvs-47-240]\]. Many attempts to reduce the development of AKI have been made, and several biomarkers, including serum creatinine (Cr) level, have been used to detect AKI. Serum Cr levels have been used as the standard indicator of renal failure for several decades, but they have several limitations, such as low sensitivity for early detection of AKI. Even in patients with more than 50% damage to the kidney, serum Cr levels can be within the normal range. Hence, more elaborate and delicate detectors for cardiac surgery-associated (CSA) AKI are needed, and several reports have shown that neutrophil gelatinase-associated lipocalin (NGAL) might be an early and novel biomarker for the detection of CSA-AKI \[[@b2-kjtcvs-47-240]\]. The aim of this study was to investigate whether increased serum NGAL levels could be a predictive biomarker of CSA-AKI.

METHODS
=======

1). Patients
------------

Thirty-seven consecutive patients who underwent elective open cardiac surgery under CPB between January 2010 and December 2012 were enrolled in this study. All of the patients underwent aortic valve annuloplasty under general anesthesia at our institution, and the operations were performed by the same surgical team. The operative approach was a standard median sternotomy, and CPB was initiated by cannulation of the ascending aorta and superior/inferior vena cava in all patients. We excluded patients who had revision cardiac surgery, other combined valvular disease, coronary artery bypass graft, off-pump cardiac surgery, severe hepatic or pulmonary disease, left ventricular ejection fraction \<40%, and pre-existing renal dysfunction (serum Cr level \>1.5 mg/dL). The following patients were also excluded from the study: (1) those aged ≥80 years of age, (2) those who had been treated with anti-thrombotic agents within 2 weeks of surgery, (3) those who had had three-vessel disease or other vascular diseases, including cerebral vascular accident, and (4) those with severe postoperative bleeding, need for reoperation, or long-standing ventilator care. We reviewed data on age, gender, height, weight, operation time, CPB time, aorta cross clamp (ACC) time, estimated glomerular filtration rate (eGFR), NGAL, and Cr levels (before, immediately after, and 24 hours after the operation); and on underlying diseases, including diabetes mellitus (DM), hypertension (HTN), hyperlipidemia, and smoking collected from the electronic medical records. Preoperative evaluation of all patients, including renal function, was within the normal range. The average age of the patients at the time of surgery was 51.84±14.48 years (range, 24 to 78 years), and the male-to-female ratio was 26:11. The clinical characteristics of the patients are summarized in [Table 1](#t1-kjtcvs-47-240){ref-type="table"}. Operative mortality was defined as death within 30 days of surgery or in-hospital death. On the basis of immediate postoperative NGAL levels, the patients were classified into either group A (n=30) or group B (n=7). Group A had immediate postoperative serum NGAL levels within the normal range, and group B had elevated immediate postoperative serum NGAL levels. Demographic data were obtained from the electronic medical records. Preoperative baseline and postoperative blood samples were analyzed for serum Cr and plasma NGAL. Postoperative samples were collected twice, at the intensive care unit (ICU) admission after completion of surgery, and on postoperative day 1. The postoperative NGAL level as a predictor of AKI after CPB was evaluated by multivariate logistic regression.

2). Plasma neutrophil gelatinase-associated lipocalin measurement
-----------------------------------------------------------------

Plasma NGAL was measured by using the Triage NGAL Test point-of-care fluorescence immunoassay (Biosite Inc., San Diego, CA, USA) with a measureable range of 15 to 3,000 ng/mL. This kit was preserved in a cold area at 2°C to 8°C, and the upper normal limit of NGAL was 150 ng/mL. Venous whole blood samples with ethylenediaminetetraacetic acid, an anticoagulant, were collected and were analyzed within 1 hour after sample collection.

3). Definition of acute kidney injury
-------------------------------------

On the basis of the definition of the Acute Kidney Injury Network (AKIN) for stage 1 AKI \[[@b3-kjtcvs-47-240]\], AKI after CPB was defined as an increase of ≥0.3 mg/dL in serum Cr or a percentage increase of ≥50% in serum Cr following CPB. Because of a confounding effect resulting from frequent diuretic use during the perioperative period, urine output was excluded from the criteria. The eGFR values were calculated using a body surface area-modified Cockroft-Gault equation. Baseline eGFR was stratified according to the guidelines of the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) \[[@b4-kjtcvs-47-240]\]: eGFR\>90 mL/min/1.73 m^2^ as 'normal renal function'; 60\<eGFR\<90 mL/min/1.73 m^2^ as 'mild decreased renal function'; 30\<eGFR\<60 mL/min/1.73 m^2^ as 'moderate decreased renal function'; 15\<eGFR\<30 mL/min/1.73 m^2^ as 'severe decreased renal function'; and eGFR\<15 mL/min/1.73 m^2^ as 'kidney failure.'

4). Statistical analysis
------------------------

Data were entered in a Microsoft Excel 2007 spreadsheet (Microsoft Co., Redmond, WA, USA) and transferred to PASW SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA) for data description and analysis. Categorical variables are expressed as frequencies and percentages, and continuous variables are expressed as mean±standard deviation. After testing for normality of distribution, continuous variables were compared using the Student unpaired t-test or the Mann-Whitney U-test. Categorical variables were compared using the chi-squared test or Fisher's exact test. Univariate and multivariate analyses were performed by linear regression analysis. A p-value of \<0.05 was considered to indicate statistical significance.

RESULTS
=======

Patients were divided into two groups according to immediate postoperative NGAL levels. Group A (n=30) had immediate postoperative serum NGAL levels within the normal range, and group B (n=7) had elevated immediate postoperative serum NGAL levels. The median ages of groups A and B were 58.97±13.02 years and 64.14±14.05 years, respectively, and the gender ratio (male:female) of groups A and B were 20:10 and 6:1, respectively. The operation times (minutes) of groups A and B were 340.03±44.12 minutes and 405.07±75.58 minutes, respectively. The CPB times (minutes) of groups A and B were 170.73±27.79 minutes and 177.57±45.93 minutes, respectively. The ACC times (minutes) of groups A and B were 111.70±24.27 minutes and 116.00±48.15 minutes, respectively. There were no statistically significant differences between the two groups in age, gender, weight, height, underlying condition, smoking, operation time, CPB time, and ACC time ([Table 1](#t1-kjtcvs-47-240){ref-type="table"}). Further information regarding NGAL, Cr levels, and AKI is presented in [Table 2](#t2-kjtcvs-47-240){ref-type="table"}. The preoperative serum NGAL levels of groups A and B were 65.51±20.84 and 76.28±26.10, respectively, the preoperative serum Cr levels of groups A and B were 0.82±0.13 and 0.95±0.83, respectively, and the preoperative serum eGFR levels of groups A and B were 98.83±16.16 and 92.79±14.25, respectively. There were no statistically significant differences in preoperative serum NGAL and Cr levels between the two groups ([Table 2](#t2-kjtcvs-47-240){ref-type="table"}). However, the immediate postoperative NGAL levels of groups A and B were 83.25±26.31 and 216.28±49.25, respectively (p\<0.01). The 24-hour postoperative Cr levels of groups A and B were 0.80±0.14 and 1.24±0.33, respectively (p\<0.01). The 24-hour postoperative eGFR levels of groups A and B were 97.93±21.12 and 69.94±18.69 (p=0.03), respectively. These were statistically significant differences between the two groups in 24-hour postoperative Cr and eGFR levels. The immediate postoperative Cr levels of groups A and B were 0.72±0.15 and 0.88±0.95, respectively, immediate postoperative eGFR levels of groups A and B were 98.26±18.46 and 89.91±19.89, respectively, and the 24-hour postoperative NGAL levels of groups A and B were 113.63±48.16 and 149.43±81.48, respectively. There were no statistically significant differences in immediate postoperative Cr levels, immediate postoperative eGFR levels, and 24-hour postoperative NGAL levels between the two groups ([Table 2](#t2-kjtcvs-47-240){ref-type="table"}). It is thought that the immediate postoperative NGAL level has a significant relationship with the 24-hour postoperative Cr level. Indeed, group B (n=7) was classified with the normal renal function, showed normal NGAL and Cr levels preoperatively, and showed elevated immediate postoperative NGAL level. Despite the elevated immediate postoperative NGAL level, the immediate postoperative Cr level of group B was noted to be within the normal range. Five patients in group B showed elevated 24-hour postoperative Cr levels and were diagnosed with AKI by a nephrologist, who received further meticulous and aggressive management to protect renal function. Despite appropriate renal protection and further management, four of these five patients showed continuously elevated serum Cr levels between days 4 and 8, and one showed a normalized Cr level on postoperative day 3. Of these five patients, two required continuous renal replacement therapy (CRRT); one was diagnosed as having AKI with oliguria on postoperative day 2, who subsequently improved after 7-day CRRT, without a need for permanent renal replacement therapy; one patient was also diagnosed as having AKI on postoperative day and treated with CRRT on postoperative day 3, but expired on postoperative day 7 due to aspiration pneumonia and sepsis. Death occurred in only one patient (1/37, 2.7%) who belonged to group B. In group A, one patient was diagnosed with AKI but did not require CRRT, and subsequently, improved by conservative management without sequelae. Of the 37 patients, six (6/37, 16.2%) were diagnosed with AKI. One patient belonged to group A (1/30, 3.3%), and five patients belonged to group B (5/7, 71.4%). Two patients in group B (2/7, 28.5%) required further renal replacement therapy. In patients with AKI (6/37, 16.2%), the postoperative NGAL levels on ICU arrival were significantly higher than the preoperative NGAL levels (208.83±78.47 vs. 75.50±11.10). Postoperative NGAL levels on ICU arrival were a significant independent predictor of AKI development and 24-hour postoperative Cr levels after cardiac surgery by multivariate logistic regression analysis with various clinical factors (age, gender, weight, height, underlying condition and smoking, operation time, CPB time, ACC time, and NGAL level) as covariates (p\<0.01; odds ratio, 72.50; 95% CI). Postoperative NGAL levels on ICU arrival and 24-hour post-operative Cr levels after cardiac surgery were significant independent predictors of AKI development. Immediate postoperative NGAL levels were significantly related to 24-hour postoperative Cr levels. Multivariate logistic regression analysis showed that 24-hour postoperative Cr levels are related to immediate postoperative NGAL levels through the following equation ([Fig. 1](#f1-kjtcvs-47-240){ref-type="fig"}).

Immediate postoperative NGAL level = −26.780+152.282×24-hour postoperative Cr level

DISCUSSION
==========

AKI reflects the entire spectrum of acute renal failure, a complex disorder that occurs in a wide variety of settings with clinical manifestations ranging from minimal elevation in serum Cr to anuric renal failure. In 2004, the standard definition for AKI was proposed by the Acute Dialysis Quality Initiative on the basis of the Risk Injury Failure Loss End Stage (RIFLE) criteria \[[@b3-kjtcvs-47-240],[@b5-kjtcvs-47-240]\]. AKI represents a significant problem in clinical medicine, with devastating immediate and long-term consequences \[[@b6-kjtcvs-47-240],[@b7-kjtcvs-47-240]\]. The incidence of AKI varies from 5% of hospitalized patients to 30% of patients at ICUs. AKI is a frequent and serious complication in about 30% to 50% of patients undergoing cardiac surgery under CPB performed worldwide \[[@b8-kjtcvs-47-240]\]. AKI requiring dialysis accounts for up to 5% of all cases, in which the mortality rate reaches 80% \[[@b9-kjtcvs-47-240]\]. Diagnosis and management of AKI constitutes one of the most important roles of the cardiac surgeon after open heart surgery \[[@b10-kjtcvs-47-240]\]. Recently, the standardized clinical definition of AKI has been implemented through the validation of the RIFLE and AKIN criteria \[[@b3-kjtcvs-47-240],[@b5-kjtcvs-47-240]\]. This standardized clinical definition using RIFLE and AKIN criteria has shown that irrespective of severity or stage, the true incidence of CSA-AKI is associated with prolonged treatment at the ICU, prolonged hospital stay, increased hospitalization cost, and increased patient morbidity/mortality \[[@b11-kjtcvs-47-240]\].

Many studies have reported that cardiac surgery under CPB is closely associated with postoperative renal injury. Fischer et al. \[[@b12-kjtcvs-47-240]\] reported that AKI after CPB occurs in about 8% of adult cardiac surgical patients with some preoperative renal impairment and in about 3% to 4% of patients with normal preoperative renal function. However, the exact etiology and pathogenesis after cardiac surgery under CPB have not yet been fully understood, although several theories and risk factors have been suspected. A plausible explanation for CSA-AKI is renal ischemia caused by hemodynamic instability and reperfusion injury during CPB. Other causes include decreased renal flow, decreased pulsatile flow, hypothermia, atheroembolism, and generalized inflammatory response \[[@b13-kjtcvs-47-240],[@b14-kjtcvs-47-240]\]. Many studies have reported that the triggering event for the CSA-AKI is often an extreme change in hemodynamics, which results in the low cardiac output state. However, CPB alone may also lead to AKI in which the glomerular filtration rate is decreased by 30% during CPB \[[@b15-kjtcvs-47-240]\]. In addition to hypothermia, vasoconstriction, and exposure to the microemboli generated by the activated cascades, structural and functional changes in the kidney may develop quickly. These changes are initiated as mild cortical or medullar edema and may proceed with the breakdown of tubular cells and result in necrosis, which is manifested as clinical symptoms and abnormal blood urea nitrogen and Cr levels as a consequence of a 30% to 40% decrease in the number of nephrons \[[@b16-kjtcvs-47-240]\]. Others have also reported that the etiologies of renal impairment related to cardiac surgery on CPB remain unclear and that there have been only a few risk factors reported, such as old age, arterial HTN, underlying DM, impaired left ventricular ejection fraction, underlying amyloidosis, history of previous nephritic attacks, and long-term CPB during cardiac surgery. Preoperative and intraoperative factors, such as age, previous level of Cr, DM, cardiac output, the duration of extracorporeal circulation, and the use of the intra-aortic balloon, have been identified as risk factors for the development of postoperative AKI in many studies \[[@b16-kjtcvs-47-240]\]. In the current practice, AKI is typically diagnosed by measuring serum Cr, which is a standard, classical, and reliable marker of renal function. Unfortunately, its constant and slow production leads to a slight increase in Cr concentration and late changes in patients with acute renal injury, and very low sensitivity for detecting early AKI. For these reasons, there remains the need for much earlier markers for AKI after cardiac surgery under CPB \[[@b17-kjtcvs-47-240]\]. Several studies have shown that novel biomarkers can detect acute tubular injury earlier than serum Cr in patients with AKI and that a majority of patients for whom tubular injury is detected with these novel biomarkers do not develop clinical AKI because the early detection leads to early management of AKI. Furthermore, most of the patients evaluated with these novel biomarkers who do go on to develop AKI experience a milder form of AKI with transient elevations in serum Cr and do not progress to more severe AKI stages or require acute dialysis \[[@b18-kjtcvs-47-240]--[@b20-kjtcvs-47-240]\].

NGAL is a protein of the lipocalin family that is highly expressed in various pathologic states and is an early biomarker of AKI in various situations, such as cardiac surgery. Compared with serum Cr, NGAL allows for earlier identification of patients with AKI. Previous studies have demonstrated that urine and plasma NGAL levels reach their peak within 6 hours after adult cardiac surgery, which predicts the development of AKI during an early postoperative period. Additionally, these biomarkers are associated with a longer hospitalization and ICU stay and higher risk of dialysis or in-hospital death. A previous study has described the role of these biomarkers in a Cr-based AKI diagnosis \[[@b21-kjtcvs-47-240]\].

NGAL is a 25,000-dalton protein belonging to the lipocalin superfamily, which is composed of 8 beta-strands that form a beta-barrel enclosing a calyx that binds and transports low molecular weight chemicals \[[@b22-kjtcvs-47-240]\]. In humans, NGAL is expressed by neutrophils and various epithelial cells and is commonly found in human organs, including the uterus, prostate, salivary gland, lung, trachea, stomach, colon, and kidney \[[@b23-kjtcvs-47-240]\]. NGAL is generally expressed at very low concentrations in several human tissues and greatly elevated in patients with epithelial damage \[[@b24-kjtcvs-47-240],[@b25-kjtcvs-47-240]\]. In healthy kidneys, it is barely detectable in either plasma or urine. However, in the setting of acute tubular injury, NGAL undergoes rapid and profound up-regulation with significant increases in both urine and plasma \[[@b11-kjtcvs-47-240]\]. Numerous studies have recently shown that NGAL binds to siderophores (iron-chelating molecules secreted by micro-organisms) and is highly expressed in various pathological states, particularly AKI. Several studies have suggested that NGAL is detected in first-stream urine and serum samples within 2 hours after ischemia and that the NGAL level correlates with the duration of renal ischemia \[[@b26-kjtcvs-47-240]\]. The first clinical application of NGAL was the detection of inflammation and sepsis as a biomarker. Bacterial infection activates neutrophil secondary granules, which secrete NGAL into the blood stream. However, although NGAL is frequently detected in renal disease and neoplastic conditions, it has limited clinical use and low sensitivity as a biomarker for infection. For these reasons, sensitivity to infection is lower in NGAL than in C-reactive protein, and thus, NGAL has not been used in clinical practice \[[@b27-kjtcvs-47-240],[@b28-kjtcvs-47-240]\]. Further studies have demonstrated that NGAL is one of the earliest and most robustly induced proteins following renal ischemia and nephrotoxic insults. NGAL can be measured in both plasma and urine samples, and both serum and urinary NGAL levels have been found to be reliable predictors of AKI in patients undergoing cardiac surgery. NGAL measurements are probably more reflective of local renal injury because they are noninvasive and relatively free of interfering proteins \[[@b29-kjtcvs-47-240]\].

NGAL is a small and ubiquitous protein of 178 amino acids with a molecular mass of approximately 25 kDa and is composed of eight beta sheets that form a calyx shaped structure. It belongs to the family of lipocalins, which are characterized by eight β-strands that form a β-barrel defining a calyx. This calyx binds and transports a wide variety of low molecular weight molecules, which are considered to determine the biologic activity of each lipocalin. It has been proven that these lipocalins are associated with many biological processes, such as inflammation, the transport of pheromones, and the synthesis of prostaglandins. Therefore, NGAL represents a critical component of immunity to bacterial infection. In fact, human NGAL was originally identified as a small protein covalently bound to the gelatinase from human neutrophils, where it represents one of the neutrophil secondary granule proteins. NGAL is expressed at very low levels in normal human tissues, including those of the kidney, trachea, lungs, stomach, uterus, salivary glands, and colon, and the expression of NGAL increases greatly in the presence of inflammation and injury to the epithelium. NGAL as a renal injury biomarker was first discovered in 2003, following experimental ischemic injury to the kidney in a mouse model. Lipocalin was the gene with the earliest and highest rise in the mRNA and protein concentration in renal tissue, urine, and plasma. Expression of NGAL protein was detected predominantly in proliferating proximal tubule cells \[[@b26-kjtcvs-47-240]\]. In 2011, Paragas et al. \[[@b30-kjtcvs-47-240]\] reported the correlation between the NGAL mRNA level produced by the kidney and the protein released from the kidney to the urine in real time. They proved that the timing and the intensity of NGAL mRNA and protein were correlated and dependent on the degree of kidney damage with renal ischemia models of mice. In addition, they found that the detection of the urinary NGAL level using mice models with the renal injury was possible after 3 hours, whereas the serum Cr level rose after about 12 hours. Further, they showed that NGAL was produced in the distal convoluted tubule and the collecting duct, while the proximal convoluted tubule was involved in the process of plasma NGAL reabsorption. Portilla et al. \[[@b31-kjtcvs-47-240]\] highlighted the role of NGAL as a marker of proximal tubule damage in a population of 40 children developing AKI after cardiac surgery. In this study, they reported that the improper functioning of the proximal tubule is related to the level of NGAL and postulated that acute renal injury resulting from hypoxic conditions could cause disruption of megalin-dependent endocytosis in the renal proximal tubule, resulting in the loss of urinary NGAL and suggesting it as a marker of proximal injury. Kuwabara et al. \[[@b32-kjtcvs-47-240]\] reported that after kidney injury, the primary source of urinary NGAL was the glomerular filtrate, and this is caused by the proximal tubule damage. Both plasma and urine NGALs are increased after a renal injury, and even though the kidney is considered the major source of elevated plasma lipocalin, there are other plausible explanations. Several studies using human and animal models have demonstrated that AKI results in an increased NGAL mRNA expression in distant organs, particularly the liver and lungs, contributing to the increased serum levels of NGAL. This effect may further increase urine levels as a result of insufficient reabsorption of NGAL at the proximal convulated tubule. Further, NGAL is an acute-phase reactant and may be released from neutrophils, macrophages, and other immune cells. Any decrease in GFR resulting from AKI would be expected to decrease the renal clearance of NGAL, with subsequent accumulation in the systemic circulation \[[@b26-kjtcvs-47-240],[@b33-kjtcvs-47-240]\].

Dehydrated situation ongoing prerenal azotemia, similar to other reasons reducing renal blood flow, the glomerular filtration rate may be decreased and glomerular epithelial cells can be damaged. In this situation, injury of the brush border of proximal tubule cells is the earliest lesion in the prerenal stage, and during this early period, minimal acute tubular necrosis cannot be detected using routine laboratory investigations such as serum Cr levels \[[@b34-kjtcvs-47-240]\]. Dehydration as a form of prerenal AKI may be represented by tubular enzymuria and a concomitant increase in serum NGAL. Although NGAL is expressed only at very low levels in several human tissues, it is markedly induced in injured epithelial cells, including the kidney. NGAL is increased in urine very early after injury (within 2 hours), and hence, NGAL may be a sensitive biomarker for detecting minimal acute renal dysfunction in dehydrated patients. The higher urinary NGAL concentrations in patients with moderate dehydration than in the mildly dehydrated ones in this study implied that the degree of dehydration affected the severity of acute kidney dysfunction \[[@b34-kjtcvs-47-240],[@b35-kjtcvs-47-240]\].

The results of this study indicate that serum NGAL may be a better predictor for CSA-AKI than serum Cr. The lack of early biomarkers for AKI after cardiac surgery under CPB may lead to an unacceptable delay in timely treatment. This study demonstrated that NGAL could be used as an indicator for the diagnosis and prognosis of CSA-AKI. As mentioned above, we showed that the postoperative NGAL level, which is characterized by more rapid onset and higher sensitivity than Cr, has a significant advantage in the early detection of AKI. It is thought that the NGAL level can be used as an early predictor of CSA-AKI.

The results of this study are subject to some limitations. First, to minimize the selection bias, this study enrolled only patients who underwent aortic valve annuloplasty by the same operative team at a single center; therefore, the number of patients was relatively small. A further study including various types of cardiac operations using CPB and a larger number of patients enrolled in multiple centers is needed. Second, this was a retrospective study based on electronic medical records. Further studies on NGAL in CSA-AKI should be planned in a prospective manner. Third, this study included only patients with normal preoperative renal function, normal preoperative eGFR, NGAL, and Cr levels. Further studies on various preoperative renal conditions, e.g., normal, mild, moderate, severely decreased, and kidney failure according to the classification based on the guideline of NKF-KDOQI, is needed. Fourth, although numerous studies on patients with AKI have shown that both urine and plasma NGAL levels are significant independent predictors of AKI, these studies differ in the range for optimum utility of this test. Depending on the studies, urine and plasma NGAL level ranges from 10 to 550 ng/mL. Hence, there is no clear spectrum to offer the pertinent application of NGAL in AKI \[[@b36-kjtcvs-47-240],[@b37-kjtcvs-47-240]\]. Therefore, a definite range for the application of both urine and plasma in CSA-AKI should be clarified, and the relationship between both urine and plasma should be established.

An elevated level of serum NGAL is associated with CSA-AKI. This biomarker shows a relatively high sensitivity and specificity in patients with CSA-AKI and provides rapid results (within 15 minutes). These results enable us to detect and manage a patient with AKI early, avoiding unnecessary administration of nephrotoxic materials, such as contrast media and antibiotics.

In conclusion, the results of this study suggest that NGAL may be an early biomarker for CSA-AKI and thus, provide a basis for early interventional strategies for the prevention of CSA-AKI. Further studies with a larger sample size and a prospective design are needed to confirm our results.
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###### 

Clinical characteristics of the patients

  Characteristic                      Group A (n=30)   Group B (n=7)   p-value
  ----------------------------------- ---------------- --------------- ---------
  Age (yr)                            58.97±13.02      64.14±14.05     0.121
  Male:female                         20:10            6:1             0.185
  Weight (kg)                         68.27±12.33      62.57±8.46      0.257
  Height (cm)                         166.93±11.98     165.71±5.28     0.796
  Body surface area (m^2^)            1.68±0.17        1.62±0.12       0.174
  Underlying condition                                                 
   Diabetes mellitus                  10 (33.3)        3 (42.8)        0.163
   Hypertension                       14 (46.7)        4 (57.1)        0.423
   Hyperlipidemia                     10 (33.3)        2 (28.5)        0.385
   Smoking                            6 (20.0)         2 (28.5)        0.248
  Operation time (min)                340.03±44.12     405.07±75.58    0.063
  Cardiopulmonary bypass time (min)   170.73±27.79     177.57±45.93    0.610
  Aortic cross clamp time (min)       111.70±24.27     116.00±48.15    0.733

Values are presented as mean±standard deviation or number (%).

###### 

AKI-related data

  Variable                 Group A (n=30)   Group B (n=7)   p-value
  ------------------------ ---------------- --------------- ---------
  Pre-OP NGAL              65.51±20.84      76.28±26.10     0.345
  Pre-OP Cr                0.82±0.13        0.95±0.83       0.503
  Pre-OP eGFR              98.83±16.16      92.79±14.25     0.074
  Immediate post-OP NGAL   83.25±26.31      216.28±49.25    \<0.001
  Immediate post-OP Cr     0.72±0.15        0.88±0.95       0.062
  Immediate post-OP eGFR   98.26±18.46      89.91±19.89     0.098
  24-hr post-OP NGAL       113.63±48.16     149.43±81.48    0.132
  24-hr post-OP Cr         0.80±0.14        1.24±0.33       \<0.001
  24-hr post-OP eGFR       97.95±21.12      69.94±18.69     0.003
  AKI                      1 (3.3)          5 (71.4)        \<0.001
  Mortality                0                1 (14.2)        0.076

Values are presented as mean±standard deviation or number (%).

AKI, acute kidney injury; OP, operation; NGAL, serum neutrophil gelatinase-associated lipocalin; Cr, serum creatinine; eGFR, estimated glomerular filtration rate.
